Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S, Pérez-Simón JA. Molinos-Quintana Á, et al. Among authors: herrero b. Front Immunol. 2024 Jan 16;14:1280580. doi: 10.3389/fimmu.2023.1280580. eCollection 2023. Front Immunol. 2024. PMID: 38292483 Free PMC article.
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
Ghorashian S, Jacoby E, De Moerloose B, Rives S, Bonney D, Shenton G, Bader P, Bodmer N, Quintana AM, Herrero B, Algeri M, Locatelli F, Vettenranta K, Gonzalez B, Attarbaschi A, Harris S, Bourquin JP, Baruchel A. Ghorashian S, et al. Among authors: herrero b. Lancet Haematol. 2022 Oct;9(10):e766-e775. doi: 10.1016/S2352-3026(22)00225-3. Epub 2022 Sep 6. Lancet Haematol. 2022. PMID: 36084658 Free article.
Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.
Diaz MA, Pérez-Martínez A, Herrero B, Deltoro N, Martinez I, Ramirez M, Abad L, Sevilla J, Merino E, Ruiz J, Vicario JL, Gonzalez-Vicent M. Diaz MA, et al. Among authors: herrero b. Bone Marrow Transplant. 2016 Sep;51(9):1211-6. doi: 10.1038/bmt.2016.101. Epub 2016 Apr 18. Bone Marrow Transplant. 2016. PMID: 27088380
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring.
Molinos-Quintana Á, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, Pérez de Soto C, Faura A, González-Martínez B, Castillo-Robleda A, Diaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S, Pérez-Simón JA. Molinos-Quintana Á, et al. Among authors: herrero b. Front Immunol. 2024 Feb 7;15:1373852. doi: 10.3389/fimmu.2024.1373852. eCollection 2024. Front Immunol. 2024. PMID: 38384474 Free PMC article.
Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study.
Molina B, Gonzalez Vicent M, Herrero B, Deltoro N, Ruiz J, Perez Martinez A, Diaz MA. Molina B, et al. Among authors: herrero b. Biol Blood Marrow Transplant. 2019 Jan;25(1):100-106. doi: 10.1016/j.bbmt.2018.08.012. Epub 2018 Aug 22. Biol Blood Marrow Transplant. 2019. PMID: 30142415 Free article. Clinical Trial.
91 results